Browsing by Author "Kaur, Palakpreet"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Effect of the Pharmacist-managed Cardiovascular Risk Reduction Services (CVRRS) on the Diabetic Retinopathy Outcome Measures
    (Office of the Vice Chancellor for Research, 2016-04-08) Kaur, Palakpreet; Gonzalvo, Jasmine; Weber, Zach; Bhatwadekar, Ashay D.
    Indianapolis Diabetes mellitus is affecting many people throughout the world. Diabetic retinopathy (DR) is a long-term complication of diabetes associated with impaired vision. If left untreated DR may eventually lead to blindness. DR is caused by a damage to the small blood vessels in the retina. According to the American Academy of Ophthalmology, 5-10 % of the diabetic patients with normal retinal exams will develop DR within a year of their last retinal exam. The diabetic individuals who currently have DR are similarly susceptible to developing more severe retinopathy. Unfortunately many individuals with diabetes fail to receive education about maintaining glycemic control, medication management and recommended frequency of tests to monitor diabetic complications such as DR. Several studies have shown that the disease management services are effective in improving the quality of care for persons with diabetes. An increasing number of disease management programs utilize pharmacists to assist in the disease management of diabetic individuals. For this clinical study we evaluated the effect of pharmacistmanaged CVRRs on the development of DR in over 100 diabetic individuals. The patient records were assessed for demographics (e.g. age, sex etc.), metabolic parameters (lipid profile, HbA1c) along with number of pharmacist appointments and ophthalmology records. We observed that 95% of the patients who have had pharmacist intervention have been able to keep their retinopathy from getting worse or have improved it. Our studies suggest that there is a correlation supporting the theory that pharmacist intervention helps manage or reduce the severity of DR. Further studies can be conducted in the area to find potential ways to help decrease the severity of DR in patients with diabetes and maybe even prevent diabetic patients from developing DR.
  • Thumbnail Image
    Item
    Rapid Development of Clinical Trial Candidates Using Cancer Systems Pharmacology: a Lymphoma Case Study
    (Office of the Vice Chancellor for Research, 2015-04-17) Arkenberg, Matthew; Johnson, Kylee; Kaur, Palakpreet; Moors, Kelly; Weisman, Michael
    Due to intrinsic complex molecular interactions, the “one disease – one target – one drug” strategy for disease treatment is no longer the best option to treat complex diseases such as cancers. To assess drug pharmacological effects, we assume that “ideal” drugs for patients can treat or prevent the disease by modulating its gene expression profile to a similar level of those in healthy people. A drug that may not have been approved to treat a cancer yet, based on its gene expression target profile is the most successfully at modulating the gene expression to being of similar level to a healthy person is known as drug repurposing. The goal of this study was to develop an in silico framework which would determine which drug(s) could be repurposed to treat more complex disease of interest such as cancers. Using three subcategories of Non-Hodgkin’s Lymphoma (Burkitt’s, Mantle, Diffuse Large B-Cell) as case studies, manual curation was done to collect data on drug-protein interaction, drug similarity analysis based on structure and protein target, and curation; disease-protein interactions, and protein-protein interactions. A network will be created from the curated data known as a Pharmacology Effect Network (PEN). The Pharmacological Effect on Target (PET) algorithm will then be used to rank the curated drugs. This ranking will help determine which of the investigated drugs not currently used to treat one of the three subsets of Non-Hodgkin’s lymphoma could possibly be recommended to treat them. Although this project was primarily done using manual curation, the framework of each curated relationship used by each curator has been incorporated into a web interface. This webpage will allow for more automation of the curation process with little help from the curator and should improve the speed and accuracy of the curation process. Mentors: Jake Chen7, Xiaogang Wu7, Walter Jessen8 7IU Center for Systems Biology and Personalized Medicine, IUPUI; 8Informatics, Covance, Greenfield